Next-Generation Histone Deacetylase Inhibitors header

About This Symposium:

Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested in pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects and unwanted toxicity. Cambridge Healthtech Institute’s eighth annual event on Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family.

New HDAC Chemistries and Screening Approaches

HDAC6 Inhibitor Platform: Therapeutic Applications in Charcot-Marie-Tooth (CMT) and Rett Syndrome

Alan P. Kozikowski, Ph.D., Professor, College of Pharmacy Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago

Characterization of HDAC Inhibitors: From Structural Analysis to Cell Function

Pascal Steiner, Ph.D., Senior Researcher, Department of Neuroscience, Genentech Inc.

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity

Yingjie Zhang, Ph.D., Lecturer, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University

Imaging HDAC Density and Drug Inhibition in the Human Brain

Jacob Hooker, Ph.D., Assistant Professor, Radiology, Harvard Medical School

Exploring HDAC Biology

Chemogenomic Approaches to Spatiotemporal Regulation of HDAC Activity

Ralph Mazitschek, Ph.D., Assistant Professor, Center for Systems Biology, Chemical Biology Platform, Massachusetts General Hospital

Targeting HDACs in Cardiovascular Disease

Timothy A. McKinsey, Ph.D., Associate Professor and Associate Division Head for Translational Research, Department of Medicine, Division of Cardiology, University of Colorado Denver

Immuno-modulatory Function of HDAC6 and Tubulin Acetylation

Tso-Pang Yao, Ph.D., Associate Professor, Department of Pharmacology and Cancer Biology, Duke University

The Roles of Class I HDACs in Alzheimer’s Disease

Li-Huei Tsai, Ph.D., Professor of Neuroscience, Department of Brain and Cognitive Sciences and Director, Picower Institute for Learning and Memory, Massachusetts Institute of Technology

Discrete and Novel Immunologic Roles of Individual Class I HDAC Enzymes 

Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Chief of Transplant Immunology, Children's Hospital of Philadelphia and University of Pennsylvania

Sponsored presentation (opportunity available)

Pan v/s Isoform-specific Inhibitors: Novel HDAC Inhibitors in the Pipeline

Clinical Potential of Isoform Selective HDAC Inhibitors

Kenneth C. Anderson, M.D., Kraft Family Professor of Medicine, Harvard Medical School, Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute

HDAC10 Controls Autophagy-mediated Drug Resistance

Olaf Witt, M,D., Professor for Pediatric Oncology, Hematology and Immunology Head, CCU Pediatric Oncology German Cancer Research Center Head, Section Pediatric Brain Tumors, Department of Pediatric Oncology, Hematology and Immunology University Children's Hospital 

Chemical Modulation of Chromatin Structure and Function

James E. Bradner, M.D., Staff Physician, Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Assistant Professor, Department of Medicine, Harvard University Medical School

Sponsored presentation (opportunity available)





green arrow VIEW ALL SPONSORS 



The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager